Awaiting product image

Philadelphia Chromosome / Bcr-Abl – Quantitative

₹6,000.00

15 minutes
Categories: ,

The Philadelphia Chromosome BCR-ABL – Quantitative Test measures the amount of BCR-ABL fusion gene in the blood or bone marrow. This gene is formed when parts of chromosome 9 and chromosome 22 break and reattach, creating an abnormal gene that leads to the production of a protein that can cause leukemia, particularly chronic myelogenous leukemia (CML).

Unlike the qualitative test, which simply detects the presence or absence of the BCR-ABL gene, this quantitative test measures the level of the gene’s expression, providing more detailed information about the disease’s progression and response to treatment.

Enquiry Here

    Description

    Why It’s Done
    The BCR-ABL Quantitative Test is typically used to:
    • Diagnose chronic myelogenous leukemia (CML) and monitor its progression.
    • Assess treatment effectiveness in patients undergoing therapy for CML, especially those on tyrosine kinase inhibitors (TKIs).
    • Monitor minimal residual disease (MRD), which refers to the small number of leukemia cells that may remain after treatment and are often undetectable by other tests.
    • Predict relapse risk: A rising level of BCR-ABL may indicate that the leukemia is returning, even if symptoms haven’t appeared yet.
    • Guide treatment decisions, helping doctors adjust therapies based on how well the leukemia is responding to treatment.

    Preparation
    • No special preparation is required for this test.
    • A blood sample is drawn from a vein in your arm, or a bone marrow sample may be used if the blood test is inconclusive.
    • Timing of the test: It’s often performed at regular intervals (e.g., every 3–6 months) during treatment to assess response to therapy and to check for potential relapse.
    • Inform your doctor about any medications or treatments you are currently undergoing, especially targeted therapies such as tyrosine kinase inhibitors.

    Related products